Abeona Therapeutics Announces New Employee Inducement Grants Under Nasdaq Listing Rule 5635(c)(4)

Group 1 - Abeona Therapeutics Inc. has granted equity awards to new non-executive employees, totaling up to 25,500 restricted shares of common stock, as a material inducement to employment [1] - The restricted stock awards will vest one-third yearly on each anniversary of the Grant Date, fully vesting on the third anniversary, contingent on continued employment [1] Group 2 - Abeona Therapeutics is a clinical-stage biopharmaceutical company focused on developing cell and gene therapies for serious diseases [2] - The U.S. FDA has accepted and granted Priority Review for the Biologics License Application for pz-cel, with a target action date of May 25, 2024 [2] - The company has a fully integrated cGMP manufacturing facility capable of supporting commercial production of pz-cel upon FDA approval [2] - Abeona's development portfolio includes AAV-based gene therapies for ophthalmic diseases, utilizing next-generation AAV capsids to improve tropism profiles [2]